Comparison of pharmacokinetics of L-carnitine, Acetyl-L-carnitine and Propionyl-Lcarnitine after single oral administration of L-carnitine in healthy volunteers
Open Access
- 1 February 2009
- journal article
- research article
- Published by University of Toronto Press Inc. (UTPress) in Clinical & Investigative Medicine
- Vol. 32 (1) , E13-E19
Abstract
Purpose: To investigate the pharmacokinetics of L-carnitine (LC) and its analogues, acetyl-L-carnitine (ALC) and propionyl -L-carnitine (PLC) in healthy volunteers after single L-carnitine administration. Methods: Liquid L-carnitine (2.0 g) was administered orally as a single dose in 12 healthy subjects. Plasma and urine concentrations of L-carnitine, ALC and PLC were detected by HPLC. Results: The maximum plasma concentration (Cmax) and area under the curve (AUC0-∞) of L-carnitine was 84.7±25.2 μmol˙L-1˙h and 2676.4±708.3 μmol˙L-1˙h, respectively. The elimination half-life of L-carnitine and the time required to reach the Cmax (Tmax) was 60.3±15.0 and 3.4±0.46 h, respectively. The Cmax of ALC (12.9±5.5 μmol˙L-1) and PLC (5.08±3.08 μmol˙L-1) was lower than L-carnitine (P < 0.01), so as the AUC0-− (166.2±77.4 and 155.6±264.2μmol˙L-1˙h, respectively, P < 0.01). The half-life of ALC (35.9±28.9h) and PLC (25.7±30.3 h) was also shorter than L-carnitine (P < 0.01). The 24h accumulated urinary excretion of L-carnitine, ALC and PLC were 613.5±161.7, 368.3±134.8 and 61.3±37.8μmol, respectively. Conclusion: L-carnitine has a greater maximum plasma concentration than ALC and PLC. L-carnitine also has a longer half-life than ALC and PLC. These data may have important implications in the designing of dosing regimens for L-carnitine or its analogues, such as ALC or PLC.Keywords
This publication has 16 references indexed in Scilit:
- Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer??s diseaseInternational Clinical Psychopharmacology, 2003
- Adjunctive therapy in anaemia managementNephrology Dialysis Transplantation, 2002
- Conditioned nutritional requirements and the pathogenesis and treatment of myocardial failureCurrent Opinion in Clinical Nutrition and Metabolic Care, 2000
- Pharmacokinetics of propionyl‐ l‐carnitine in humans: evidence for saturable tubular reabsorptionBritish Journal of Clinical Pharmacology, 2000
- Carnitine: An osmolyte that plays a metabolic roleJournal of Cellular Biochemistry, 2000
- Uptake of L-carnitine by a human intestinal epithelial cell line, Caco- 2Gastroenterology, 1996
- Multiple‐Dose Pharmacokinetics and Bioequivalence L-Carnitine 330-mg Tablet versus 1-g Chewable Tablet versus Enteral Solution in Healthy Adult Male VolunteersJournal of Pharmaceutical Sciences, 1995
- Quantitative estimation of absorption and degradation of a carnitine supplement by human adultsMetabolism, 1991
- In vivo studies of intestinal carnitine absorption in ratsGastroenterology, 1985
- Absorption of d- and l-carnitine by the intestine and kidney tubule in the ratBiochimica et Biophysica Acta (BBA) - Biomembranes, 1984